These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18953708)

  • 1. Words of wisdom. Re: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European randomized study of screening for prostate cancer (Rotterdam). Wolters T, Roobol MJ, Bangma CH, Schröder PH.
    Scattoni V
    Eur Urol; 2008 Oct; 54(4):945-6. PubMed ID: 18953708
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Terris MK
    Eur Urol; 2009 Feb; 55(2):392; discussion 393. PubMed ID: 18353530
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
    Shteynshlyuger A; Andriole GL
    J Urol; 2011 Mar; 185(3):828-32. PubMed ID: 21239021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Monique J. Roobol, Fritz H. Schröder, Pim van Leeuwen, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81.
    Connolly D; Hutton R; Keane PF
    Eur Urol; 2011 Mar; 59(3):e9; author reply e10-1. PubMed ID: 21145647
    [No Abstract]   [Full Text] [Related]  

  • 5. Updated results from the European Randomized Study of Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: are Asian countries encouraged to promote PSA screening?
    Sugimoto M; Kakehi Y
    Asian J Androl; 2012 Jul; 14(4):522-4. PubMed ID: 22751444
    [No Abstract]   [Full Text] [Related]  

  • 6. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening.
    Ciatto S; Zappa M; Villers A; Paez A; Otto SJ; Auvinen A
    BJU Int; 2003 Dec; 92 Suppl 2():97-100. PubMed ID: 14983964
    [No Abstract]   [Full Text] [Related]  

  • 7. Screening for prostatic cancer and its evolution within Britain.
    Parkinson MC; Bott SR; Montironi R; Melia J
    J Pathol; 2002 Jun; 197(2):139-42. PubMed ID: 12015735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Otto SJ; van der Cruijsen IW; Liem MK; Korfage IJ; Lous JJ; Schröder FH; de Koning HJ
    Int J Cancer; 2003 Jun; 105(3):394-9. PubMed ID: 12704675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The story of the European Randomized Study of Screening for Prostate Cancer.
    Schröder FH; Denis LJ; Roobol M; Nelen V; Auvinen A; Tammela T; Villers A; Rebillard X; Ciatto S; Zappa M; Berenguer A; Paez A; Hugosson J; Lodding P; Recker F; Kwiatkowski M; Kirkels WJ;
    BJU Int; 2003 Dec; 92 Suppl 2():1-13. PubMed ID: 14983946
    [No Abstract]   [Full Text] [Related]  

  • 10. Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.
    Ilic D
    Recent Results Cancer Res; 2014; 202():65-71. PubMed ID: 24531779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No randomised trial of prostate-cancer screening in Norway.
    Fosså SD; Eri LM; Skovlund E; Tveter K; Vatten L;
    Lancet Oncol; 2001 Dec; 2(12):741-5; discussion 746-9. PubMed ID: 11902516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In depth analysis of 2 studies of prostate cancer screening--what makes sense?].
    Recker F
    Praxis (Bern 1994); 2010 Feb; 99(3):183-5. PubMed ID: 20127638
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PSA related screening of prostate cancer. Panic or improvement?].
    Fornara P; Jurczok A
    Aktuelle Urol; 2004 Feb; 35(1):43-8. PubMed ID: 14997414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simulated screening for prostate cancer: the useful model.
    Church TR
    J Natl Cancer Inst; 2003 Jun; 95(12):838-9. PubMed ID: 12813160
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate-specific antigen: a new(ish) study.
    Harv Mens Health Watch; 2010 Nov; 15(4):6-8. PubMed ID: 21166115
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA Screening for Prostate Cancer.
    Quaas J
    Am Fam Physician; 2015 May; 91(9):Online. PubMed ID: 25955746
    [No Abstract]   [Full Text] [Related]  

  • 19. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Wolters T; Roobol MJ; Bangma CH; Schröder FH
    Eur Urol; 2009 Feb; 55(2):385-92. PubMed ID: 18353529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rural residence and prostate cancer screening with prostate-specific antigen.
    Stamatiou K; Skolarikos A
    Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.